Scandion Oncology will present at Sedermeradagen on November 18, 2019, in StockholmCEO Nils Brünner will present news from Scandion Oncology at Sedermeradagen i...
Peter Høngaard - our new Chairman of the Board - is portrayed and interview by BioStockThe full interview and portray with Peter Høngaard can be read below,...
Scandion Oncology CEO Newsletter autumn 2019Nils Brünner, CEO, has summarized the current activities of Scandion Oncology...
Scandion Oncology will present on the Nordic Rise Launch Party#Scandion Oncology will join the Launch Party of Nordic Rise on Thursday 26. ...
Investor Lunch in Copenhagen on Oct 1st#Scandion Oncology looks very much forward to present at an investor lunch in...
BioStock presentation of Scandion Oncology and the ongoing Rights IssueBioStock has made a nice background about Scandion Oncology and the ongoing R...
Unit Rights for shareholdersDear Investor and current shareholder in Scandion Oncology, As a reminder ...
Rights Issue investor presentation in Copenhagen on June 25CEO Nils Brünner will present Scandion Oncology and the Rights Issue in Copen...
Scandion Oncology is now a member of Nordic RiseScandion Oncology has joined Nordic Rise, which is a focussed, ambitious and ...
Presentation and interview from BioStock LiveCEO Nils Brünner presented Scandion Oncology at the investor meeting "BioStoc...
Rights Issue investor presentations next weekCEO Nils Brünner will present Scandion Oncology and the Rights Issue at 4 inv...
CEO Nils Brünner presents today at the investor meeting "BioStock Live investerarträff"CEO Nils Brünner will present today at the investor meeting "BioStock Live in...
Watch the presentation from Småbolagsdagen 2019 in StockholmCEO Nils Brünner presented at the investor meeting Småbolagsdagen 2019 in Sto...
Scandion Oncology presents at the investor meeting Småbolagsdagen 2019 in StockholmCEO Nils Brünner will present Scandion Oncology to more than 400 investors in...
Scandion Oncology presentation from Öresundsdagen investor meetingCEO Nils Brünner presented Scandion Oncology at the Öresundsdagen investor me...
Scandion Oncology will present at Öresundsdagen in Malmö on May 20This a kind reminder that you can meet Scandion Oncology on Monday 20th in Ma...
Joint investor meeting with 2cureX on April 30On April 30...
Scandion Oncology presented in BerlingskeToday, in Berlingske there is a special issue on "Fremtidens Investeringer". ...
Scandion Oncology presentation from SedermeradagenCEO Nils Brünner presented the status and the plans for Scandion Oncology at ...
Production of SCO-101 is following the planScandion Oncology had on February 28, 2019, a face-to-face meeting with our d...
Scandion Oncology will present at Sedermeradagen in Copenhagen on March 12Sedermeradagen will take place on March 12 at the Marriott Hotel in Copenhage...
Scandion Oncology has today moved to new facilities at SymbionToday Scandion Oncology has moved to new facilities at Symbion (Fruebjergvej ...
Strategy meeting in Scandion OncologyThe BoD and management of Scandion Oncology gathered at Karlaby Kro on Dec. 1...
Presentation at the 13th Annual EORTC PatoBiology Group Meeting on September 15, 2018 in Hamburg, GermanyCSO Jan Stenvang will present data on SCO-101 and endocrine resistance in br...
Presentation at the conference “Response and Resistance in Cancer therapy” on September 10, 2018 in Kent, UKCEO Nils Brünner will present data on SCO-101 and endocrine resistance in br...
Presentation at the conference “Response and Resistance in Cancer therapy” on September 9, 2018 in Kent, UKCEO Nils Brünner will present data on SCO-101 and chemotherapy resistance at ...
Scandion has submitted a patent application regarding a novel mechanism of action for its lead compound SCO-101Scandion Oncology has discovered a novel mechanism of action for its lead com...
Scandion Oncology A/S presents at the MVA Oncology Network Pitch event at Medicon Village, Lund, Sweden, September 5th, 2018CSO Jan Stenvang will pitch the background and status of Scandion Oncology A/...
Thomas Feldthus has joined the Board of Scandion OncologyThomas Feldthus has joined the Board of Scandion Oncology. Thomas Feldthus re...
Scandion Oncology A/S signs agreement with Sedermera Fondkommission AB regarding an Initial Public Offering at Spotlight Stock Market.Scandion Oncology A/S hereby announces that an agreement has been signed w...
Scandion Oncology A/S hereby announces that an agreement has been signed w...
Scandion Oncology A/S presents at Sedermeradagen, Malmö, Sweden May 15th 2018Sedermeradagen is an investor day where Scandion Oncology A/S will present to...
Scandion Oncology A/S meets with Big Pharma at ”Focus on Cancer Collaboration” at Medicon Village, Lund, Sweden April 24thCMO Nils Brünner will present the background and status of Scandion Oncology ...
InnoBooster grant from Innovation Fund DenmarkScandion Oncology has been awarded an InnoBoster grant from Innovation Fund D...
Presentation at Danish Association for Cancer ResearchScandion Oncology will present data on SCO-101 at the annual meeting “Danish ...
Presentation at ESMO GIScandion Oncology will present data on SCO-101 at ESMO GI in Barcelona, Spain...
Saniona Spin-Out, Scandion Oncology Raises DKK 2 Million and Prepares for a Potential Public ListingSaniona, a leading biotech company in the field of ion channels, today announ...
Abstracts and poster presentations on October 28, 2017Abstracts and poster presentations on October 28, 2017, at the AACR-NCI-EORTC...
Poster presentation on November 1, 2017Poster presentation on November 1, 2017, at the Biomarker AGORA 2017, Copenha...
